ACHC · Acadia Healthcare Company, Inc.

Current Thesis

Acadia Healthcare's turnaround case requires confirmation of its July earnings outlook and a weekly recovery above the surrendered $30.20 shelf before a weekly close below $27. The 2026-09-18 reference close of $28.33 leaves that recovery unconfirmed. The operating anchor remains the company's 2026-07-28 guidance for fiscal 2026 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $590–615 million; that is a dated management forecast, not a measured outcome.

The material change since September 6 is positioning. The earlier description of a shrinking short base no longer describes the latest observation. This reversal does not establish a sustained accumulation trend or predict forced covering. MarketBeat short-interest history

As a price-structure inference, the narrative is dead as an established July breakout: the 2026-09-04 close of $28.13 and the 2026-09-18 close of $28.33 both sit beneath the previously identified $30.20 shelf. A weekly close above that shelf would overturn this classification. The prospective recovery case has low conviction because the supplied price record has not confirmed it.

Bullish and bearish views on Acadia Healthcare Company, Inc.

The model's bull view on Acadia Healthcare Company, Inc. (ACHC), in brief: Management raised the annual floor. The 2026-07-28 results raised fiscal 2026 adjusted EBITDA guidance to $590–615 million from $580–615 million and adjusted earnings per share to $1.45–1.60 from $1.35–1.60. These company forecasts support the operating-recovery case; a… The bear view: Quarterly earnings still contracted. The 2026-07-28 release reported second-quarter adjusted EBITDA of $149.2 million against $201.8 million a year earlier, and adjusted earnings per share of $0.38 against $0.83. A higher annual forecast does not erase the reported quarterly… Both cases follow in full.

Bull Case

• Management raised the annual floor. The 2026-07-28 results raised fiscal 2026 adjusted EBITDA guidance to $590–615 million from $580–615 million and adjusted earnings per share to $1.45–1.60 from $1.35–1.60. These company forecasts support the operating-recovery case; a subsequent reduction would weaken it.
• Underlying patient activity remained positive. The 2026-07-28 results reported second-quarter patient-day growth of 0.8% and same-facility revenue growth of 3.2% after adjusting for supplemental-payment timing. The timing-adjusted figure is the company's presentation, rather than the flat reported same-facility result.
• Cash guidance exceeded capital spending. Management's 2026-07-28 fiscal 2026 outlook called for operating cash flow of $350–400 million and capital expenditure of $235–255 million. Actual cash generation and subsequent legal payments remain necessary tests of that forecast.

Bear Case

• Quarterly earnings still contracted. The 2026-07-28 release reported second-quarter adjusted EBITDA of $149.2 million against $201.8 million a year earlier, and adjusted earnings per share of $0.38 against $0.83. A higher annual forecast does not erase the reported quarterly deterioration.
• Liability reserves absorbed operating earnings. The same release reported a $39.3 million increase in professional and general liability costs, including a $28.6 million reserve adjustment for expected settlements. Another disclosed reserve increase would challenge the interpretation that this pressure is stabilizing.
• Supplemental payments complicate comparisons. Second-quarter 2026 results included $22.3 million of Florida supplemental payments relating to the prior state fiscal year, according to the 2026-07-28 disclosure. Their absence in a subsequent quarter would require a timing reconciliation; absence alone would not prove weaker patient demand.

Setup & Price Structure

The supplied adjusted-price series records a 2026-09-18 close of $28.33, a three-month increase of 12.4%, and a price 20.4% below the $35.61 trailing-year high. The 14-period relative strength index was 48.6. These observations show a retained three-month advance alongside an unrecovered breakout shelf; no moving-average value was supplied to establish support from that measure.

The $30.20 shelf remains the recovery condition identified in the September 6 research, while $27 remains its published thesis boundary. The available September closes do not establish that every intervening weekly close remained within those levels.

Crowding coverage has returned: Benzinga's 2026-09-14 squeeze-candidate article listed Acadia with short interest equal to 37.26% of float. MarketBeat reports 24.55% for the 2026-08-31 settlement. Those percentages cannot establish a change in crowding without reconciled float definitions and observation dates. One article also cannot establish clustered retail participation or an imminent squeeze. Benzinga screening article, MarketBeat short-interest data

Catalyst Calendar (next 30 days)

• 2026-09-24 — Short-interest publication. The Financial Industry Regulatory Authority (FINRA) schedules publication of the 2026-09-15 settlement snapshot on this date. It provides the next observation after the August increase, rather than a real-time measure of covering. FINRA calendar
• 2026-10-09 — Short-interest publication. FINRA schedules publication of the 2026-09-30 settlement snapshot on this date. It supplies another observation for assessing whether the August reversal persisted. FINRA calendar
• ~2026-11-04, estimated — Third-quarter results. Outside the next 30 days, MarketBeat estimates this reporting date from historical schedules; company confirmation is absent from the reviewed earnings evidence. This replaces the earlier late-October estimate. The release tests the July earnings outlook, supplemental-payment timing and liability reserves. MarketBeat earnings calendar

What Would Change Our Mind

Failure of the published $27 boundary would end the recovery thesis: a weekly close below $27 is the observable price invalidation. Conversely, a weekly close above the surrendered $30.20 shelf would overturn the failed-breakout assessment; confirmation of the 2026-07-28 earnings outlook at the third-quarter release would complete the stated recovery case.

A reduction below the July forecast's $590 million adjusted-EBITDA floor would independently undermine the operating premise. Another professional and general liability reserve adjustment would require reassessment, particularly if management also reduced that outlook. Missing Florida supplemental revenue alone would be insufficient without the company's timing explanation.

Correlation Notes

This remains a single-company turnaround assessment within health services. The 2026-07-28 Florida payment disclosure and liability-reserve adjustment identify specific operating exposures; neither establishes a measured relationship with a healthcare index or another provider.

Benzinga's 2026-09-14 list places Acadia alongside unrelated squeeze candidates. That is evidence of shared screening coverage, not measured return correlation. No paired return sample establishes a group-driven explanation for Acadia's 2026-09-18 price structure.